Use of methylene blue for refractory septic shock during continuous venovenous hemodiafiltration

Pharmacotherapy

Volumn 30, Issue 3, 2010, Pages

  Mount, Joshua C ^a   Rowe, A Shaun ^b  

^a Johnson City Medical Center   (United States)

^b UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

Continuous renal replacement therapy; Continuous venovenous hemodiafiltration; CRRT; CVVHDF; Hypotension; Methylene blue; Sepsis; Shock

Indexed keywords

AMIKACIN; CASPOFUNGIN; CATECHOLAMINE; COLISTIMETHATE; DROTRECOGIN; HYDROCORTISONE; MEROPENEM; METHYLENE BLUE; NORADRENALIN; PHENYLEPHRINE; VANCOMYCIN; VASOPRESSIN; NITRIC OXIDE; VASOCONSTRICTOR AGENT;

ACUTE KIDNEY FAILURE; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS INFUSION; CONTINUOUS RENAL REPLACEMENT THERAPY; DRUG DOSE TITRATION; HUMAN; LABORATORY TEST; MALE; MEAN ARTERIAL PRESSURE; SEPSIS; SEPTIC SHOCK; THORAX RADIOGRAPHY; TRAFFIC ACCIDENT; ULTRAVIOLET SPECTROSCOPY; WEANING; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG RESISTANCE; FATALITY; HEMODIAFILTRATION; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ACCIDENTS, TRAFFIC; BLOOD PRESSURE; CATECHOLAMINES; DRUG RESISTANCE; FATAL OUTCOME; HEMODIAFILTRATION; HUMANS; KIDNEY FAILURE, ACUTE; MALE; METHYLENE BLUE; MIDDLE AGED; NITRIC OXIDE; RENAL REPLACEMENT THERAPY; SEPSIS; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS;

EID: 77649228928     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.3.323     Document Type: Article

References (20)

1. Schneider F, Lutun P, Hasselmann M, Stoclet JC, Tempe JD. Methylene blue increases systemic vascular resistance in human septic shock: preliminary observations. Intensive Care Med 1992:18(5):309-11.
2. Andresen M, Dougnac A, Diaz O, et al. Use of methylene blue in patients with refractory septic shock: impact on hemodynamics and gas exchange. J Crit Care 1998;13(4): 164-8.
3. Avontuur JA, Bruining HA, Ince C. Inhibition of nitric oxide synthesis causes myocardial ischemia in endotoxemic rats. Circ Res 1995;76(3):418-25.
4. Brown G, Frankl D, Phang T. Continuous infusion of methylene blue for septic shock. Postgrad Med J 1996;72(852):612-14.
5. Cheng X, Pang CC. Pressor and vasoconstrictor effects of methylene blue in endotoxaemic rats. Naunyn Schmiedebergs Arch Pharmacol 1998;357(6):648-53.
6. Daemen-Gubbels CR, Groeneveld PH, Groeneveld AB, van Kamp GJ, Bronsveld W, Thijs LG. Methylene blue increases myocardial function in septic shock. Crit Care Med 1995;23(8):1363-70.
7. Galili Y, Kluger Y, Mianski Z, et al. Methylene blue: a promising treatment modality in sepsis induced by bowel perforation. Eur Surg Res 1997;29(5):390-5.
8. Hata JS, Dellinger RP. Nitric oxide inhibition in the treatment of septic shock. Crit Care Med 1995;23(10):1621-4.
9. Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med 2001;29(10):1860-7.
10. Memis D, Karamanlioglu B, Yuksel M, Gemlik I, Pamukcu Z. The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care 2002;30(6): 755-62.
11. Park BK, Shim TS, Lim CM, et al. The effects of methylene blue on hemodynamic parameters and cytokine levels in refractory septic shock. Korean J Intern Med 2005;20(2):123-8.
12. Preiser JC, Lejeune P, Roman A, et al. Methylene blue administration in septic shock: a clinical trial. Crit Care Med 1995;23(2):259-64.
13. Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother 1998;32(3):362-75.
14. O'Reilly P, Tolwani A. Renal replacement therapy III: IHD, CRRT, SLED. Crit Care Clin 2005;21(2):367-78.
15. Kontos HA, Wei EP. Hydroxyl radical-dependent inactivation of guanylate cyclase in cerebral arterioles by methylene blue and by LY83583. Stroke 1993;24(3):427-34.
16. Marczin N, Ryan US, Catravas JD. Methylene blue inhibits nitrovasodilator- and endothelium-derived relaxing factor-induced cyclic GMP accumulation in cultured pulmonary arterial smooth muscle cells via generation of superoxide anion. J Pharmacol Exper Ther 1992;263(1):170-9.
17. Wolin MS, Cherry PD, Rodenburg JM, Messina EJ, Kaley G. Methylene blue inhibits vasodilation of skeletal muscle arterioles to acetylcholine and nitric oxide via the extracellular generation of superoxide anion. J Pharmacol Exper Ther 1990;254(3):872-6.
18. Peer G, Itzhakov E, Wollman Y, et al. Methylene blue, a nitric oxide inhibitor, prevents haemodialysis hypotension. Nephrol Dial Transplant 2001;16(7):1436-41.
19. Kozaki A, Watanabe J. Dose dependency of apparent volumes of distribution for methylene blue in rabbits. J Pharmacobiodyn 1981;4(1):49-57.
20. Gerskowitch VP, Hodge J, Hull RA, et al. Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist. Br J Clin Pharmacol 2007;63(5):618-22.